OncoMatch/Clinical Trials/NCT06951997
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Is NCT06951997 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including QL1706 and Chidamide for metastatic pancreatic cancer.
Treatment: QL1706 · Chidamide · Gemcitabine · Nab-paclitaxel — This is a single-center, open-label, exploratory study aims to assess the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Excluded: BRCA1 germline mutation
Excluded: BRCA2 germline mutation
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-CTLA-4)
Prior treatment with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1/CTLA-4 antibodies)
Cannot have received: immune checkpoint agonist (anti-ICOS, anti-CD40, anti-CD137, anti-GITR, anti-OX40)
immune checkpoint agonists (e.g., anti-ICOS/CD40/CD137/GITR/OX40 antibodies)
Cannot have received: immune cell therapy (CAR-T)
immune cell therapy (e.g., CAR-T)
Lab requirements
Blood counts
platelet count ≥90x10^9/l, white blood cell count ≥ 3.5 × 10⁹/l, absolute neutrophil count (anc) ≥1.5x10^9/l, hemoglobin > 90g/l
Kidney function
urea/urea nitrogen (bun) and creatinine (cr) ≤ 1.5 × uln (and creatinine clearance rate (ccr) ≥ 50 ml/min)
Liver function
ast and alt ≤ 2.5 times uln, total bilirubin ≤ 1.5 uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ 50%, qtcf interval (fridericia correction) < 470 ms
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06951997 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Are patients with BRCA1 alterations eligible?
No. BRCA1 germline mutation is an exclusion criterion.
Are patients with BRCA2 alterations eligible?
No. BRCA2 germline mutation is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages